Prostate specific antigen after external beam radiotherapy for prostatic cancer: Followup

I. D. Kaplan, R. S. Cox, M. A. Bagshaw, P. C. Walsh

Research output: Contribution to journalArticlepeer-review

141 Scopus citations


Between 1986 and 1989, 117 patients with pretreatment and serial posttreatment prostate specific antigen values received external beam radiotherapy at our hospital. Followup ranged from 0.6 to 5.9 years (mean 2.7). No patient had hormonal manipulation before distant recurrence. Biochemical relapse, defined as an increasing prostate specific antigen level after treatment, was observed in 44 patients. To date 30 of these 44 patients (68%) have had clinical relapse. The prognostic factors of advanced local stage, high Gleason score and high elevations of pretreatment prostate specific antigen values predicted for biochemical relapse and subsequent clinical failure. The interval between biochemical and clinical relapse was 156 ± 46 days. Biochemical relapse is an important end point that can be used to determine the effect of treatment in prostatic cancer research.

Original languageEnglish (US)
Pages (from-to)519-522
Number of pages4
JournalJournal of Urology
Issue number3
StatePublished - 1993
Externally publishedYes


  • antigens, neoplasm
  • prostatic neoplasms
  • radiotherapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Prostate specific antigen after external beam radiotherapy for prostatic cancer: Followup'. Together they form a unique fingerprint.

Cite this